MilliporeSigma
Accelerate. Scale. Implement.
BioReliance® End-to-End Solutions encompass service and support for both emerging biotech as well as major biopharmaceutical companies that seek to accelerate process development, clinical drug production, and conceptual facilities design. As a trusted partner, we facilitate success by enabling our clients at any step from early-stage Process Development through commercial Facilities Design - anywhere in the world - having flexible solutions that optimize performance and providing guidance based upon first-hand experience. We operate our own in-house bioproduction facilities and convey our expertise to clients as they progress along their drug development journey. Combining the strengths of all that is MilliporeSigma, with an emphasis on Single-Use technologies and high-performance upstream and downstream systems, please visit our website for more information.
MilliporeSigma
BIO International Booth #1518
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
